DK2435583T3 - miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI - Google Patents
miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFIInfo
- Publication number
- DK2435583T3 DK2435583T3 DK10723982T DK10723982T DK2435583T3 DK 2435583 T3 DK2435583 T3 DK 2435583T3 DK 10723982 T DK10723982 T DK 10723982T DK 10723982 T DK10723982 T DK 10723982T DK 2435583 T3 DK2435583 T3 DK 2435583T3
- Authority
- DK
- Denmark
- Prior art keywords
- duchennes
- mir
- treatment
- muscle
- drops
- Prior art date
Links
- 108091060585 Mir-31 Proteins 0.000 title 1
- 210000003205 muscle Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20090161038 EP2258863A1 (en) | 2009-05-25 | 2009-05-25 | miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics |
| PCT/EP2010/057093 WO2010136417A1 (en) | 2009-05-25 | 2010-05-24 | miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2435583T3 true DK2435583T3 (da) | 2014-09-29 |
Family
ID=40718989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10723982T DK2435583T3 (da) | 2009-05-25 | 2010-05-24 | miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9034838B2 (da) |
| EP (1) | EP2435583B1 (da) |
| DK (1) | DK2435583T3 (da) |
| WO (1) | WO2010136417A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1766010T3 (da) | 2004-06-28 | 2011-06-06 | Univ Western Australia | Antisense-oligonukleotider til induktion af exon-skipping og fremgangsmåder til anvendelse deraf |
| IL313162A (en) | 2008-10-24 | 2024-07-01 | Sarepta Therapeutics Inc | Antisense compounds for inducing axon termination and preparations containing them for the treatment of muscular dystrophy |
| KR20230137491A (ko) | 2009-11-12 | 2023-10-04 | 더 유니버시티 오브 웨스턴 오스트레일리아 | 안티센스 분자 및 이를 이용한 질환 치료방법 |
| EP2535412A1 (en) * | 2011-06-17 | 2012-12-19 | Universitat Pompeu-Fabra | New treatment for muscular dystrophies |
| KR20230116945A (ko) | 2013-03-14 | 2023-08-04 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 엑손 스키핑 조성물 |
| KR20150133768A (ko) | 2013-03-15 | 2015-11-30 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 개선된 조성물 |
| US9637738B2 (en) | 2013-04-10 | 2017-05-02 | Reveragen Biopharma, Inc. | Methods and agents to increase therapeutic dystrophin expression in muscle |
| EP3598978B1 (en) | 2018-07-26 | 2024-05-29 | EXOFIX S.r.l. | Fibroadipogenic progenitor-derived exosomes for regeneration of dystrophic muscles |
| EP4215614A1 (en) | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| EP2281888B1 (en) | 2004-11-12 | 2015-01-07 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| CA2663962A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
| WO2008142567A2 (en) * | 2007-05-18 | 2008-11-27 | Karolinska Institutet Innovations Ab | Microrna molecules associated with inflammatory skin disorders |
-
2010
- 2010-05-24 DK DK10723982T patent/DK2435583T3/da active
- 2010-05-24 EP EP20100723982 patent/EP2435583B1/en not_active Not-in-force
- 2010-05-24 WO PCT/EP2010/057093 patent/WO2010136417A1/en not_active Ceased
- 2010-05-24 US US13/322,023 patent/US9034838B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2435583A1 (en) | 2012-04-04 |
| US20120129920A1 (en) | 2012-05-24 |
| WO2010136417A1 (en) | 2010-12-02 |
| US9034838B2 (en) | 2015-05-19 |
| EP2435583B1 (en) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2448637T4 (da) | Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi | |
| DK2293816T3 (da) | Fremgangsmåder til behandling af reumatoid arthritis | |
| BRPI1010197A2 (pt) | métodos e compostos de pirazolopirimidina jak | |
| ZA201006648B (en) | Methods of treatment | |
| DK2435583T3 (da) | miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI | |
| DK2329012T3 (da) | Behandling af slagtilfælde under anvendelse af isolerede placentaceller | |
| DK3517534T3 (da) | Forbindelser, der er anvendelige til behandling af cancer | |
| EP2254597A4 (en) | TREATMENT PROCEDURE WITH ANTI-MIF ANTIBODIES | |
| DK2498771T3 (da) | Anvendelse af bethanechol til behandling af xerostomi | |
| PL2283114T3 (pl) | Traktowanie komórek pluripotencjalnych | |
| DK2350116T3 (da) | Behandling af biofilm | |
| EP3422006C0 (en) | DETECTION OF A RISK OF PRE-ECLAMPSIA | |
| PL2506850T3 (pl) | Sposoby podawania terapii pirfenidonem | |
| DK3124610T3 (da) | Hbv-behandling | |
| DK2373927T3 (da) | Behandling af forbrændingsgas fra affaldsbehandling | |
| IL207170A0 (en) | Methods of treating viral infections | |
| BRPI0919127A2 (pt) | métodos para tratamento de água | |
| BR112014015551A8 (pt) | método para tratar lama e método para desidratação de lama | |
| DK2358714T3 (da) | Alkylcyclohexylethere af dihydrotetraazabenzoazulener | |
| DK2382232T3 (da) | Fremgangsmåde til fremstilling af bivalirudin | |
| BRPI0916079A2 (pt) | tratamento de água marinha residual | |
| DK2554172T3 (da) | Fremgangsmåde til behandling af sygdomme | |
| DK2501381T3 (da) | Behandling af atrieflimmer | |
| HRP20160577T1 (hr) | Liječenje osteoartritisa | |
| HRP20181116T1 (hr) | Koncentrati za tretiranje supstrata |